tissue sample News
-
Crossbay medical announces ce mark marketing authorization for its endometrial tissue sampler (ETS)
CrossBay Medical, Inc., today announced that it has received clearance to commercialize its product, the Endometrial Tissue Sampler using CrossGlide™ technology, in Europe by obtaining its CE Mark. The use of this technology allows a novel way to obtain an office-based endometrial biopsy, a very common tissue-sampling procedure performed in women’s health offices worldwide. The ETS is ...
-
Exploring Biomarkers for Regorafenib Response in Metastatic Colorectal Cancer with the Precellys Evolution
Colorectal cancer affects the colon or rectum and is on the rise among young adults. Lifestyle factors like diet and physical inactivity may contribute to its incidence. Early detection through regular screenings is crucial for effective management. Awareness of symptoms and risk factors is essential for timely intervention. The 4th of February marks the World Cancer Day. In this publication, ...
-
SAGA Diagnostics enters into Development Agreement with AstraZeneca
SAGA Diagnostics AB, a cancer liquid biopsy and genomic testing company focused on precision oncology and non-invasive ultrasensitive monitoring of cancer patients, has entered into an assay development agreement with the global, science-led biopharmaceutical company AstraZeneca (LSE/STO/Nasdaq: AZN). SAGA Diagnostics will in the course of this agreement develop unique SAGAsafe® dPCR ...
-
SAGA expands research collaboration with University College London Cancer Institute
SAGA Diagnostics AB, a cancer liquid biopsy and genomic testing company focused on precision oncology and non-invasive ultrasensitive monitoring of cancer patients, today announced an expanded research collaboration with Professor Charles Swanton, at the University College London (UCL) Cancer Institute. Last year, SAGA and UCL entered into a research collaboration on a limited number of ...
-
Dako, an Agilent Technologies Company, Launches Two Ready-to-Use Antibodies for Cancer Diagnosis
Dako, an Agilent Technologies company and worldwide provider of cancer diagnostic solutions, today announced the addition of two new antibodies, Anti-CK 8/18 and Anti-TdT, to the Dako portfolio of high-quality reagents, instruments and software. Anti-CK 8/18 is the first rabbit monoclonal antibody cocktail for cytokeratin 8/18 (CK 8/18) available from a major pathology provider. It is used by ...
-
U.S. Food and Drug Administration Clears UVision360, Inc. Novel LUMINELLE® 360° Bx (Biopsy) Sheath
UVision360, Inc., an innovative medical device company, announces today that the U.S. Food and Drug Administration (FDA) has approved the patented LUMINELLE 360° Bx (Biopsy) Sheath which expands the capability of the LUMINELLE® DTx System. The LUMINELLE 360° Bx sheath, combined with the LUMINELLE DTx System, is the first and only integrated directed biopsy device not requiring ...
By LUMINELLE
-
Startup Licenses UA-Invented Disruptive Biopsy Device
The University of Arizona has licensed the design for a next-generation needle biopsy instrument that utilizes electrosurgery and electrocautery to safely increase tissue sample volumes in minimally invasive biopsy procedures. The licensee is a startup company, Data Driven Diagnostics Sciences Inc., also known as D3Sciences, or D3S. The inventing team includes Dr. Michael Larson, resident ...
-
Agilent Technologies Introduces IQFISH FFPE Buffer, Enabling One-Hour Hybridization of FFPE Tissue Samples
Agilent Technologies Inc. (NYSE: A) today introduced the IQFISH FFPE Hybridization buffer, which enables one-hour hybridization for FISH processing on formalin fixed paraffin embedded (FFPE) tissue samples. The IQ technology, originally developed by Dako, was previously available only to anatomic pathology labs. Now, with the IQFISH FFPE Hybridization buffer offered as a standalone product, ...
-
Application of Whole-Genome Sequencing in Older Esophageal Carcinoma FFPE Tissues Reveals Novel Insights
Collection of fresh-frozen tumor samples is often challenging or infeasible, leading many studies to rely on formalin-fixed, paraffin-embedded (FFPE) tumor tissue samples. Because these tissues are often paired with a great deal of clinical and outcome data, analysis of these archives has the potential to lead to major advances in cancer treatment and prevention. Whole-genome sequencing (WGS) ...
-
Elucid’s Next-Generation Plaque Analysis and FFRCT Technology to be Featured on 2022 AHA Scientific Sessions Program
BOSTON – November 4, 2022 – Elucid, Inc., a medical technology company providing physicians AI-powered imaging analysis software to characterize cardiovascular disease, has announced that the company’s technology will be featured on the program at the 2022 American Heart Association (AHA) Scientific Sessions, November 5-7, 2022 in Chicago. Elucid has developed FDA-cleared ...
By Elucid
-
CD BioSciences Announces Comprehensive Range of Nervous System Tissue Microarrays
CD BioSciences, a US-based biotechnology company focusing on the development of imaging technologies, proudly announces an extensive portfolio of Nervous System Tissue Microarrays designed to support neuroscience research. This comprehensive collection provides researchers with a unique resource to study various neurological conditions and accelerate their investigations into neurological ...
-
CELLINK and Atelerix team up to enable the shipping at room temperature of fragile 3D bioprinted constructs by the world’s bioprinting community
CELLINK and Atelerix announced today a partnership to bring to market Atelerix’s portfolio of innovative hydrogel biological encapsulation products, which preserve fragile biological samples for shipping at room temperature. Conventional shipping methods often involve storing cells and tissues in liquid nitrogen or dry ice, which requires a freeze-thaw process notorious for ...
By Atelerix Ltd
-
Sonic Incytes Showcases Velacur at ACG 2021
Breakthrough imaging solution for liver health offers physicians an accurate, accessible and affordable way to manage emerging health crisis In recognition of Liver Awareness Month this October, Sonic Incytes Medical Corp. is pleased to showcase VelacurTM, the first handheld 3D liver health assessment solution, at the American College of Gastroenterology (ACG) Annual Scientific Meeting, ...
-
New Research Shows Progression to Esophageal Cancer as Detected by WATS3D
A newly published study as lead article in Gastrointestinal Endoscopy shows that Barrett’s esophagus (BE) and dysplasia progress to esophageal cancer at similar, or even higher, rates when diagnosed by WATS3D (wide-area transepithelial sampling with three-dimensional analysis) as they do when diagnosed by conventional forceps biopsies. This study titled “Progression of ...
-
Guided Therapeutics and U.S. FDA Agree on Meeting Date to Plan Path Forward for LuViva Advanced Cervical Scan Premarket Approval Application
Guided Therapeutics, Inc. (OTCQB:GTHP), the maker of a rapid and painless testing platform based on its patented biophotonic technology, announced today it will meet with the U.S. Food and Drug Administration (FDA) November 6, 2015, to review the company’s plan to submit an approvable application for the LuViva® Advanced Cervical Scan. The LuViva is designed to detect cervical ...
-
Agilent Introduces CGH+SNP cancer microarrays and Cytogenomics software for cancer research
Agilent Technologies Inc., (NYSE: A) today introduced SurePrint G3 CGH+SNP cancer catalog microarrays, addressing the growing need of researchers to detect both copy number and copy-neutral aberrations in cancer tissue samples in the same experiment. The new microarray release is accompanied by the release of Agilent CytoGenomics 2.0 software, which now includes support for CGH+SNP analysis of ...
-
Artificial Intelligence Can Help Doctors Diagnose Brain Tumors During Surgery. Here’s How.
A new laser-imaging technology and artificial intelligence are poised to significantly advance what neurosurgeons can do to help patients with brain tumors by potentially improving diagnostic accuracy and cutting testing turnaround time from 30 minutes or more to less than three minutes. A new imaging technique and artificial intelligence (AI) are poised to significantly advance what ...
-
Femasys Inc. Announces First Patient Treated in Pivotal Trial for FemaSeed
First in Class Insemination Treatment for Infertility LOCAL Pivotal Trial to Enroll Up to 792 Patients Across 20 U.S. Centers Femasys Inc. (NASDAQ: FEMY), a biomedical company focused on transforming women's healthcare, today announced the initiation and first patient treated in a pivotal trial evaluating FemaSeed, a first in class, localized directional insemination product candidate for ...
By Femasys Inc.
-
Elucid Appoints Dr. Michael Lesh to Board of Directors
BOSTON, November 3, 2022 – Elucid, Inc., a leading medical technology company providing physicians with AI-powered imaging analysis software to characterize cardiovascular disease, today announced the addition of Michael D. Lesh, MD, FACC, to its Board of Directors. “We look forward to what Dr. Lesh will bring to the board with his extensive background as a cardiologist, medtech ...
By Elucid
-
AI ‘Fingerprinting’ Fights Back Against Hard-to-Detect Cancers
Hard-to-detect cancers like glioblastoma can have survival rates in the single-digit percentages and require elaborate techniques to detect, treat, and monitor. Reveal Surgical is working on changing that reality through its new, AI-based Sentry technology, which leverages a combination of AI and Raman spectroscopy to provide real-time tissue diagnostics during surgery for otherwise-invisible ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you